AWP
CRL icon

Ascent Wealth Partners’s Charles River Laboratories CRL Stock Holding History

Ascent Wealth Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,279
Closed -$831K – 120
2019
Q3 		$831K Buy
6,279
+200
+3% +$26.8K 0.25% 66
2019
Q2 		$863K Buy
6,079
+260
+4% +$35.3K 0.27% 67
2019
Q1 		$845K Buy
5,819
+451
+8% +$59.3K 0.28% 66
2018
Q4 		$608K Sell
5,368
-40
-0.7% -$5.01K 0.24% 74
2018
Q3 		$728K Buy
5,408
+111
+2% +$13.7K 0.23% 81
2018
Q2 		$594K Buy
5,297
+29
+0.6% +$3.13K 0.21% 82
2018
Q1 		$562K Buy
5,268
+30
+0.6% +$3.23K 0.2% 84
2017
Q4 		$573K Buy
5,238
+8
+0.2% +$871 0.21% 83
2017
Q3 		$565K Buy
5,230
+160
+3% +$16.4K 0.23% 79
2017
Q2 		$513K Sell
5,070
-5
-0.1% -$460 0.22% 82
2017
Q1 		$456K Buy
5,075
+25
+0.5% +$2.12K 0.21% 82
2016
Q4 		$385K Buy
+5,050
New +$384K 0.19% 88

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Ascent Wealth Partners's CRL Position: Q4 2019 in Review

Ascent Wealth Partners sold out of Charles River Laboratories (CRL) in Q4 2019, closing a stake of 6,279 shares — an estimated $831K sold.

Ascent Wealth Partners first reported a position in CRL in Q4 2016 and held it in 12 quarters. The position peaked at $863K in Q2 2019. 413 funds tracked by Wall St. Rank hold CRL as of Q4 2019.

  • Ascent Wealth Partners reported no remaining Charles River Laboratories position as of Q4 2019 after selling out during the quarter.
  • Ascent Wealth Partners sold 6,279 Charles River Laboratories shares in Q4 2019, an estimated $831K.
  • Ascent Wealth Partners first reported a position in Charles River Laboratories in Q4 2016 and held it in 12 quarters.
  • Ascent Wealth Partners's Charles River Laboratories position peaked at $863K in Q2 2019.
  • 413 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2019.

Based on Ascent Wealth Partners's 13F filing for Q4 2019, filed 29 Jan 2020.